Donors after circulatory death heart trial

2021 ◽  
Vol 17 (1) ◽  
pp. 11-17
Author(s):  
Yasuhiro Shudo ◽  
Rhodalene Benjamin-Addy ◽  
Tiffany K Koyano ◽  
William Hiesinger ◽  
John W MacArthur ◽  
...  
Keyword(s):  
Heart Failure ◽  
Gold Standard ◽  
Orthotopic Heart Transplantation ◽  
Donation After Circulatory Death ◽  
Clinical Trial Registration ◽  
Life Saving ◽  
End Stage Heart Failure ◽  
Standard Life ◽  
End Stage ◽  
Circulatory Death

Orthotopic heart transplantation is the gold standard treatment for end-stage heart failure. However, the persistent shortage of available donor organs has resulted in an ever-increasing waitlist and longer waiting periods for transplantation. On the contrary, increasing the number of heart transplants by preserving extended criteria donors and donation after circulatory death hearts with the Organ Care System™ (OCS) Heart System has the potential to provide the gold standard, life-saving treatment to patients with end-stage heart failure. The objective of the Donation After Circulatory Death Heart Trial is to evaluate the effectiveness of the OCS Heart System to preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation, which can potentially provide patients with end-stage heart failure with the life-saving treatment. Clinical Trial Registration: NCT03831048 ( ClinicalTrials.gov )

scholarly journals Concurrent End-Stage Cardiomyopathy and Aortic Disease in Patients with Marfan Syndrome: A Case Report and Literature Review

2021 ◽  
Author(s):  
Timothy Smith ◽  
Jose Sleiman ◽  
Nikita Zadneulitca ◽  
Cedric Sheffield ◽  
Viviana Navas ◽  
...  
Keyword(s):  
Heart Failure ◽  
Case Report ◽  
Literature Review ◽  
Marfan Syndrome ◽  
Aortic Disease ◽  
Connective Tissue Disorder ◽  
Orthotopic Heart Transplantation ◽  
Bentall Procedure ◽  
Life Saving ◽  
End Stage

Abstract Background: Marfan syndrome (MFS) is a connective tissue disorder that can lead to aortic disease, arrhythmias and heart failure. Many centers are reluctant to offer orthotopic heart transplantation (OHT) for patients with MFS with concurrent aortic disease due to complexity of the surgery and perceived inferior results when compared to patients without MFS. Methods: We present a case of a patient with MFS with previous Bentall procedure who underwent successful OHT, accompanied by a literature review on OHT performed for patients with MFS. Results and Conclusions: Patients with MFS who underwent OHT had no difference in mortality compared to patients without MFS. Even though OHT is technically more challenging when combined with concurrent intervention for aortic disease, it should be considered as a life-saving operation for patients with MFS.

scholarly journals New Insights in the Diagnosis and Treatment of Heart Failure

2015 ◽  
Vol 2015 ◽  
pp. 1-16 ◽  
Author(s):  
Giulio Agnetti ◽  
Massimo F. Piepoli ◽  
Giuseppe Siniscalchi ◽  
Francesco Nicolini
Keyword(s):  
Heart Failure ◽  
Gold Standard ◽  
Diagnosis And Treatment ◽  
Coronary Syndrome ◽  
Developing Heart ◽  
Standard Medical Therapy ◽  
The Us ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Surgical Treatments

Cardiovascular disease is the leading cause of mortality in the US and in westernized countries with ischemic heart disease accounting for the majority of these deaths. Paradoxically, the improvements in the medical and surgical treatments of acute coronary syndrome are leading to an increasing number of “survivors” who are then developing heart failure. Despite considerable advances in its management, the gold standard for the treatment of end-stage heart failure patients remains heart transplantation. Nevertheless, this procedure can be offered only to a small percentage of patients who could benefit from a new heart due to the limited availability of donor organs. The aim of this review is to evaluate the safety and efficacy of innovative approaches in the diagnosis and treatment of patients refractory to standard medical therapy and excluded from cardiac transplantation lists.

scholarly journals Orthotopic Heart Transplantation and Mechanical Circulatory Support in Cancer Survivors: Challenges and Outcomes

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Nina Ghosh ◽  
John Hilton
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Mechanical Circulatory Support ◽  
Significant Proportion ◽  
Left Ventricular ◽  
Circulatory Support ◽  
Orthotopic Heart Transplantation ◽  
Advanced Therapies ◽  
End Stage Heart Failure ◽  
End Stage

Chemotherapy-induced cardiomyopathy (CCMP) is a significant cause of morbidity and mortality. Compared to cardiomyopathy due to other causes, anthracycline-induced cardiomyopathy is associated with a worse survival. As cancer survival improves, patients with CCMP can be expected to comprise a significant proportion of patients who may require advanced therapies such as inotropic support, cardiac transplantation, or left ventricular assist device (LVAD). Distinct outcomes related to advanced therapies for end-stage heart failure in this patient population may arise due to unique demographic characteristics and comorbidities. We review recent literature regarding the characteristics of patients who have survived cancer undergoing orthotopic heart transplantation and mechanical circulatory support for end-stage heart failure. The challenges and outcomes of advanced therapies for heart failure related specifically to anthracycline-induced cardiomyopathy are emphasized.

Sign in / Sign up

Export Citation Format

Share Document